The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience
| Autor: | Joanna Bidiuk, Zbigniew A. Gaciong, Piotr Sobieraj |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Archives of Medical Science, Vol 18, Iss 4, Pp 1095-1099 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1734-1922 1896-9151 |
| DOI: | 10.5114/aoms/150029 |
| Popis: | Introduction Recently published case reports suggest the benefit of empagliflozin use in subjects with glycogen storage disease Ib (GSD Ib). Material and methods We present the clinical and laboratory data of 2 adult brothers with GSD Ib treated with empagliflozin for 12 months. Results There was no severe infection during administration of empagliflozin. The improvement of clinical symptoms of inflammatory bowel disease and arthritis along with reduction in serum CRP levels and urinary albumin excretion were noted. Neutrophil count increased allowing for reduction or temporary withdrawal of G-CSF treatment. Conclusions Empagliflozin may be new safe treatment in GSD Ib patients with advanced stage of the disease. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|